Cambridge Research Park is delighted to welcome leading bio-tech company Grifols as the new occupants of units 8 and 9 at Enterprise, the park’s latest hybrid business unit scheme. Founded in Spain in 1909, Grifols is a global company and leading supplier of blood plasma-based products.

Grifols has subsidiaries in 30 countries and regions and on March 25th 2020 entered into a formal collaboration with the US Government to produce the first treatment specifically targeting COVID-19.